MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fcimb.2024.1437704

Медицинская библиотека · Frontiers in cellular and infection microbiology · 2024

Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ-population-based follow-up of two cluster-randomized trials.

Lehtinen Matti, Gray Penelope, Luostarinen Tapio, Eriksson Tiina, Apter Dan, Bly Anne, Harjula Katja, Heikkilä Kaisa, Hokkanen Mari, Kuortti Marjo, Nieminen Pekka, Nummela Mervi, Paavonen Jorma, Palmroth Johanna, Petäjä Tiina, Pimenoff Ville N, Pukkala Eero, Dillner Joakim

СтатьяСравнительное исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

We report head-to-head comparison of the bivalent and quadrivalent HPV vaccine efficacies against immediate precursors of cervical cancer from 15 years' country-wide cancer registry follow-up of phase III trial cohorts and an age-aligned cohort of unvaccinated women.

METHODS

These individually and/or clusterrandomized cohorts of HPV6/11/16/18- and HPV16/18-vaccinated and unvaccinated women were enrolled, respectively, in 2002, 2004, and 2003/2005. The trial cohorts comprised initially 16- to 17-year-old HPV6/11/16/18-vaccinated FUTURE II (NCT00092534) participants (866) and HPV16/18-vaccinated PATRICIA (NCT00122681) and 012 trial (NCT00169494) participants (2,465), and 16,526 initially 16- to 19-year-old unvaccinated controls. After active 4-year clinical follow-up, passive, country-wide Finnish Cancer Registry (FCR) follow-up for cervical intraepithelial neoplasia grade 3 (CIN3) and adenocarcinoma in situ (AIS) was based on consented use of unique personal identifiers and started 6 months after the end of the FUTURE II and PATRICIA trials in 2007 and 2009, and ended at the end of 2019. The follow-up with altogether 229,020 follow-up years was age-aligned to ensure that similarly aged cohorts were passively followed up for 15 years post=vaccination for the intention-to-treat analyses of vaccine efficacy.

RESULTS

Overall, we identified 5 and 16 CIN3 (no AIS) cases in the HPV6/11/16/18 and HPV16/18 cohorts, respectively, during the FCR-based follow-up. In the unvaccinated cohort, we identified 281 CIN3 cases, 20 AIS cases, and 13 cases with invasive cervical cancer. Vaccine efficacies against CIN3+ were 68.4% and 64.5% for the quadrivalent and the bivalent vaccines, respectively, with overlapping confidence intervals.

DISCUSSION: Long-term follow-up of randomized, initially adolescent HPV-vaccinated and unvaccinated cohorts shows, in this head-to-head setting, that the bivalent and quadrivalent HPV vaccines are equally effective against immediate precursors of cervical cancer.

Для цитирования: Lehtinen Matti, Gray Penelope, Luostarinen Tapio, Eriksson Tiina, Apter Dan, Bly Anne, Harjula Katja, Heikkilä Kaisa, Hokkanen Mari, Kuortti Marjo, Nieminen Pekka, Nummela Mervi, Paavonen Jorma, Palmroth Johanna, Petäjä Tiina, Pimenoff Ville N, Pukkala Eero, Dillner Joakim. Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ-population-based follow-up of two cluster-randomized trials.. Frontiers in cellular and infection microbiology. 2024. DOI: 10.3389/fcimb.2024.1437704.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.